Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document

Johnson Fistel, PLLP is investigating whether Replimune Group, Inc. (NASDAQ: REPL) or certain of its executive officers violated state or federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. If you purchased Replimune securities and suffered losses on your investment, you may join our investigation now. On July 28, 2026, the FDA released briefing documents raising significant concerns about the evidence supporting Replimune’s investigational RP1 therapy in combination with nivolumab. FDA staff concluded that the IGNYTE trial was not adequate and well controlled and that the available data could not establish whether RP1 contributed to the observed treatment effect. Following this news Replimune shares fell approximately 30%. In light of these disclosures, Johnson Fistel is investigating whether Replimune misrepresented or failed to timely disclose material information concerning RP1 and its regulatory prospects.